Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Oncotarget|April 29, 2016
Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)Sun Min Lim, Hye Ryun Kim, Eun Kyung Cho, et al.
Journal of Korean Medical Science|July 16, 2013
Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitorJae-Heon Jeong, Byoung Chul Cho, Hyo Sup Shim, et al.
Therapeutic Advances in Medical Oncology|December 22, 2022
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapyJii Bum Lee, Hyung Soon Park, Su Jin Choi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2022
Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCSeung Yeon Oh, You Won Lee, Eun Ji Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancerSun Min Lim, Hyun Chang, Yoon Jin Cha, et al.
Cell Reports. Medicine|January 28, 2025
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLCSeung Yeon Oh, Sewon Park, Seoyoung Lee, et al.
Therapeutic Advances in Medical Oncology|January 17, 2022
Predicting treatment outcomes using <sup>18</sup>F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapyChang Gon Kim, Sang Hyun Hwang, Kyung Hwan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)Sun Min Lim, Byoung Chul Cho, Sang-We Kim, et al.
JAMA Network Open|February 9, 2024
Epidemiology and Outcomes of Non-Small Cell Lung Cancer in South KoreaHyun Ae Jung, Dae Ho Lee, Sun Min Lim, et al.
JAMA Oncology|August 15, 2024
Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled TrialMin Hee Hong, Yoon Ji Choi, Hee Kyung Ahn, et al.
Pageof 14